Talazoparib-d4

Talazoparib-d4 (BMN-673-d4) is deuterium labeled Talazoparib. Talazoparib (BMN-673) is a highly potent, orally active PARP1/2 inhibitor.Talazoparib inhibits PARP1 and PARP2 enzyme activity with Kis of 1.2 nM and 0.87 nM, respectively. Talazoparib has antitumor activity[1].

Product Specifications

Product Name Alternative

BMN-673-d4; LT-673-d4

UNSPSC

12352005

Target

Isotope-Labeled Compounds; PARP

Related Pathways

Cell Cycle/DNA Damage; Epigenetics; Others

Applications

Cancer-programmed cell death

Field of Research

Cancer

Smiles

CN1C([C@H]2C(C3=C(N[C@@H]2C4=C(C([2H])=C(F)C([2H])=C4[2H])[2H])C=C(F)C=C35)=NNC5=O)=NC=N1

Molecular Formula

C19H10D4F2N6O

Molecular Weight

384.38

References & Citations

[1]Russak EM, et al. Impact of Deuterium Substitution on the Pharmacokinetics of Pharmaceuticals. Ann Pharmacother. 2019;53 (2) :211-216.|[2]Shen Y, et al. BMN 673, a novel and highly potent PARP1/2 inhibitor for the treatment of human cancers with DNA repair deficiency.Clin Cancer Res. 2013 Sep 15;19 (18) :5003-15.|[3]Wang B, et al. Discovery and Characterization of (8S,9R) -5-Fluoro-8- (4-fluorophenyl) -9- (1-methyl-1H-1,2,4-triazol-5-yl) -2,7,8,9-tetrahydro-3H-pyrido[4,3,2-de]phthalazin-3-one (BMN 673, Talazoparib), a Novel, Highly Potent, and Orally Efficacious Poly (ADP-ribose) Polymerase-1/2 Inhibitor, as an Anticancer Agent. J Med Chem. 2016 Jan 14;59 (1) :335-57.